|
RE(ACT) Congress
|
|
0
|
4
|
October 10, 2024
|
|
EUFEPS, ÖPhG | Pharmaceutical Sciences in the Heart of Europe
|
|
0
|
9
|
October 4, 2024
|
|
What are the differences between medical isotopes, nuclear medicine and radiopharmaceuticals?
|
|
0
|
12
|
July 2, 2024
|
|
Interphex 2025 | nyc
|
|
0
|
15
|
July 25, 2024
|
|
Congres Goed Gebruik Geneesmiddelen 2025
|
|
0
|
9
|
September 6, 2024
|
|
DIA Europe 2025 | Basel
|
|
0
|
11
|
July 25, 2024
|
|
FIGON Dutch Medicine Days (DMD) - 16 en 17 OKT 2024
|
|
0
|
16
|
July 15, 2024
|
|
Pharma 2025, Reuters Events | Barcelona
|
|
0
|
10
|
July 25, 2024
|
|
What are the current guidelines for environmental risk assessments of ATMPs, particularly those involving GMOs?
|
|
1
|
26
|
September 9, 2024
|
|
What are the current regulatory pathways for ATMPs in the EU and how do they compare with those in the US?
|
|
0
|
8
|
August 30, 2024
|
|
What can medical centres do to anticipate future ATMP therapies, how can they improve their centre readiness?
|
|
0
|
12
|
August 30, 2024
|
|
What regulations and legislation I need to take in to account when registering a radiopharmaceuticals in the EU?
|
|
0
|
8
|
August 28, 2024
|
|
Are there specific GMP requirements for radiopharmaceuticals to be used in a phase I clinical study?
|
|
0
|
8
|
August 28, 2024
|
|
Which medical isotopes are currently used in clinical practice and what are the advantages and disadvantages of the different medical isotopes?
|
|
0
|
10
|
August 28, 2024
|
|
Drug repurposing in rare diseases
|
|
2
|
46
|
August 21, 2024
|